Exelixis
EXEL
#1691
Rank
ยฃ7.76 B
Marketcap
ยฃ27.19
Share price
-1.71%
Change (1 day)
59.13%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Earnings for Exelixis (EXEL)

Earnings in 2024 (TTM): ยฃ0.46 Billion

According to Exelixis's latest financial reports the company's current earnings are ยฃ2.08 Billion. In 2023 the company made an earning of ยฃ0.20 Billion, an increase over its 2022 earnings that were of ยฃ0.18 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Exelixis from 2000 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) ยฃ0.46 B129.72%
2023 ยฃ0.20 B9.89%
2022 ยฃ0.18 B-20.33%
2021 ยฃ0.23 B124.82%
2020 ยฃ0.10 B-67.14%
2019 ยฃ0.31 B-11.94%
2018 ยฃ0.35 B185.09%
2017 ยฃ0.12 B-325.82%
2016 -ยฃ55.44 Million-58.12%
2015 -ยฃ0.14 Billion-37.61%
2014 -ยฃ0.22 Billion9.75%
2013 -ยฃ0.2 Billion65.96%
2012 -ยฃ0.12 Billion-291.63%
2011 ยฃ60.77 M-195.59%
2010 -ยฃ63.58 Million-42.17%
2009 -ยฃ0.11 Billion-18.98%
2008 -ยฃ0.14 Billion-6.99%
2007 -ยฃ0.15 Billion46.3%
2006 -ยฃ99.74 Million33.25%
2005 -ยฃ74.85 Million-30.92%
2004 -ยฃ0.11 Billion44.29%
2003 -ยฃ75.09 Million12.86%
2002 -ยฃ66.54 Million22.79%
2001 -ยฃ54.19 Million60.14%
2000 -ยฃ33.84 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
ยฃ3.29 B 595.25%๐Ÿ‡ฌ๐Ÿ‡ง UK
ยฃ5.84 B 1,134.83%๐Ÿ‡ซ๐Ÿ‡ท France
ยฃ13.01 B 2,648.76%๐Ÿ‡บ๐Ÿ‡ธ USA
-ยฃ5.44 Billion-1,246.85%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ3.69 B 679.96%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ14.52 B 2,966.31%๐Ÿ‡บ๐Ÿ‡ธ USA
-ยฃ0.96 Billion-302.03%๐Ÿ‡บ๐Ÿ‡ธ USA
-ยฃ36.8 Million-107.77%๐Ÿ‡บ๐Ÿ‡ธ USA
-ยฃ22.93 Million-104.84%๐Ÿ‡บ๐Ÿ‡ธ USA